Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.
作者信息
Purdue M P, Lan Q, Kemp T J, Hildesheim A, Weinstein S J, Hofmann J N, Virtamo J, Albanes D, Pinto L A, Rothman N
机构信息
1] Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, MD, USA [2] Ontario Institute for Cancer Research, Toronto, ON, Canada.
Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, MD, USA.
出版信息
Leukemia. 2015 Jun;29(6):1429-31. doi: 10.1038/leu.2015.2. Epub 2014 Jan 8.
Abstract
摘要
相似文献
1
Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.在诊断前长达二十年的时间里，血清可溶性CD23和可溶性CD30升高与非霍奇金淋巴瘤风险增加相关。
Leukemia. 2015 Jun;29(6):1429-31. doi: 10.1038/leu.2015.2. Epub 2014 Jan 8.
2
Can serum soluble CD23 or CD30 predict the occurrence of lymphoma in HIV-infected patients?
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e58-61. doi: 10.1097/QAI.0b013e31821dbbcf.
3
Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.相隔 15 年采集的预诊断样本中的循环 sCD27 和 sCD30 与未来非霍奇金淋巴瘤风险。
Int J Cancer. 2019 Apr 15;144(8):1780-1785. doi: 10.1002/ijc.31879. Epub 2018 Dec 19.
4
Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.血清可溶性CD23水平与艾滋病相关非霍奇金淋巴瘤的后续发展相关。
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84.
5
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.血清可溶性CD30浓度与非霍奇金淋巴瘤风险的前瞻性研究。
Blood. 2009 Sep 24;114(13):2730-2. doi: 10.1182/blood-2009-04-217521. Epub 2009 Jul 28.
6
Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.前瞻性血清 sCD27 和 sCD30 连续样本与非霍奇金淋巴瘤亚型风险的相关性。
Int J Cancer. 2020 Jun 15;146(12):3312-3319. doi: 10.1002/ijc.32684. Epub 2019 Oct 11.
7
Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with absence of Epstein-Barr virus in tumor tissue.
Clin Immunol. 1999 Dec;93(3):239-44. doi: 10.1006/clim.1999.4793.
8
Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood.脐带血中的可溶性CD30和CD23与儿童早期的特应性无关。
Pediatr Allergy Immunol. 2000 Nov;11(4):220-4. doi: 10.1034/j.1399-3038.2000.00094.x.
9
Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.可溶性CD23和肿瘤坏死因子α血清水平在低度非霍奇金淋巴瘤中的临床意义
Eur J Haematol. 1996 Nov;57(5):335-40. doi: 10.1111/j.1600-0609.1996.tb01390.x.
10
Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.血清可溶性CD30和白细胞介素6水平升高以及可检测到的白细胞介素10出现在经典型霍奇金淋巴瘤诊断之前。
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1114-1123. doi: 10.1158/1055-9965.EPI-16-1012. Epub 2017 Mar 24.
引用本文的文献
1
Multi-Cohort High-Dimensional Proteomics Reveals Early Risk Markers for Lymphoid Cancer Subtypes.多队列高维蛋白质组学揭示淋巴癌亚型的早期风险标志物。
Res Sq. 2025 Aug 19:rs.3.rs-7400676. doi: 10.21203/rs.3.rs-7400676/v1.
2
Elevation of circulating TNF receptor 2 in cancer: A systematic meta-analysis for its potential as a diagnostic cancer biomarker.循环肿瘤坏死因子受体 2 水平升高与癌症相关：作为一种潜在的癌症诊断生物标志物的系统荟萃分析。
Front Immunol. 2022 Nov 16;13:918254. doi: 10.3389/fimmu.2022.918254. eCollection 2022.
3
Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.在诊断前免疫激活血清生物标志物的纵向变化与 B 细胞 NHL 亚型的风险。
Cancer Epidemiol Biomarkers Prev. 2023 Feb 6;32(2):233-241. doi: 10.1158/1055-9965.EPI-22-0247.
4
Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.循环免疫标志物与非霍奇金淋巴瘤亚型风险：一项汇总分析。
Int J Cancer. 2023 Mar 1;152(5):865-878. doi: 10.1002/ijc.34299. Epub 2022 Oct 5.
5
Potential Utility of Systemic Plasma Biomarkers for Evaluation of Pediatric Schistosomiasis in Western Kenya.系统血浆生物标志物在评估肯尼亚西部小儿血吸虫病中的潜在应用。
Front Immunol. 2022 May 6;13:887213. doi: 10.3389/fimmu.2022.887213. eCollection 2022.
6
Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.前瞻性血清 sCD27 和 sCD30 连续样本与非霍奇金淋巴瘤亚型风险的相关性。
Int J Cancer. 2020 Jun 15;146(12):3312-3319. doi: 10.1002/ijc.32684. Epub 2019 Oct 11.
7
Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.免疫激活与炎症标志物及非霍奇金淋巴瘤：前瞻性研究的荟萃分析
JNCI Cancer Spectr. 2018 Dec;2(4):pky082. doi: 10.1093/jncics/pky082. Epub 2019 Mar 5.
8
Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.相隔 15 年采集的预诊断样本中的循环 sCD27 和 sCD30 与未来非霍奇金淋巴瘤风险。
Int J Cancer. 2019 Apr 15;144(8):1780-1785. doi: 10.1002/ijc.31879. Epub 2018 Dec 19.
9
Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.前瞻性队列研究中诊断前血浆免疫标志物与非霍奇金淋巴瘤风险的关系。
Haematologica. 2018 Oct;103(10):1679-1687. doi: 10.3324/haematol.2017.183236. Epub 2018 Jun 21.
10
The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma.肥胖相关激素和细胞因子水平与多发性骨髓瘤及非霍奇金淋巴瘤的关系
Front Oncol. 2018 Apr 16;8:103. doi: 10.3389/fonc.2018.00103. eCollection 2018.
本文引用的文献
1
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.一项针对 67 种血清免疫和炎症标志物与非霍奇金淋巴瘤风险的前瞻性研究。
Blood. 2013 Aug 8;122(6):951-7. doi: 10.1182/blood-2013-01-481077. Epub 2013 Jun 27.
2
Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.B 细胞活化标志物与非霍奇金淋巴瘤风险的关系。
Cancer Res. 2012 Sep 15;72(18):4733-43. doi: 10.1158/0008-5472.CAN-12-1639. Epub 2012 Jul 30.
3
Clinical aspects of monoclonal B-cell lymphocytosis.单克隆 B 细胞淋巴增生的临床方面。
Cancer Control. 2012 Jan;19(1):8-17. doi: 10.1177/107327481201900102.
4
Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population.循环可溶性 CD30 与淋巴瘤的未来风险；来自普通人群中两项前瞻性研究的证据。
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1925-7. doi: 10.1158/1055-9965.EPI-11-0396. Epub 2011 Jul 22.
5
Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.诊断前血清细胞因子和其他免疫标志物水平与非霍奇金淋巴瘤风险。
Cancer Res. 2011 Jul 15;71(14):4898-907. doi: 10.1158/0008-5472.CAN-11-0165. Epub 2011 Jun 1.
6
Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma.免疫激活和炎症的预诊断生物标志物评估：对淋巴瘤病因学的深入了解。
J Proteome Res. 2011 Jan 7;10(1):113-9. doi: 10.1021/pr100729z. Epub 2010 Oct 1.
7
Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.循环细胞因子与 B 细胞非霍奇金淋巴瘤风险：一项前瞻性研究。
Cancer Causes Control. 2010 Aug;21(8):1323-33. doi: 10.1007/s10552-010-9560-3. Epub 2010 Apr 7.
8
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.血清可溶性CD30浓度与非霍奇金淋巴瘤风险的前瞻性研究。
Blood. 2009 Sep 24;114(13):2730-2. doi: 10.1182/blood-2009-04-217521. Epub 2009 Jul 28.
9
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?肿瘤坏死因子受体（TNFR）家族的共刺激成员：有效T细胞免疫的关键？
Nat Rev Immunol. 2003 Aug;3(8):609-20. doi: 10.1038/nri1148.
10
The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group.α-生育酚、β-胡萝卜素肺癌预防研究：设计、方法、参与者特征及依从性。ATBC癌症预防研究组
Ann Epidemiol. 1994 Jan;4(1):1-10. doi: 10.1016/1047-2797(94)90036-1.
Zotero 插件